Discussant Report from the ESC Congress 2013 – SAVOR TIMI 53 Trial
by Michel Komajda (pictured right) – DPP4 inhibitors are a new class of glucose lowering agents which act on the incretin pathway.
by Michel Komajda (pictured right) – DPP4 inhibitors are a new class of glucose lowering agents which act on the incretin pathway.
by Bruce Sylvester – Research presented on September 26, 2013 the European Association for the Study of Diabetes (EASD) annual meeting in Barcelona, Spain, indicates that type 2… read more.
by Bruce Sylvester – Alogliptin treatment of patients with type 2 diabetes and with high cardiovascular risk due to recent acute coronary syndromes has led to similar rates… read more.
by Bruce Sylvester – Researchers report that, after a decade when prescription opioid use has grown dramatically, identification and treatment of pain has not improved, and, notably, the… read more.
Among patients with non-ST-segment elevation acute coronary syndrome (ACS), pretreatment with prasugrel before angiography did not improve outcomes and worsened bleeding, a randomized trial showed.
Study presenter Deepak Bhatt (pictured) – The anti-hyperglycemic agent saxagliptin neither increased or decreased therate of ischemic events when added to standard of care in patients with type… read more.
A review of the presentation by Volker Heinemann (pictured). The decision on first line treatment in mCRC matters because the number of patients benefitting from therapy diminishes with… read more.
by Pam Harrison – MSI status has clear prognostic value in stage II CRC Julien Taieb, MD, PhD, University of Paris Descartes, Paris, France Microsatellite instability (MSI), a… read more.
World Health Matters by Gary Finnegan – China – An international team of scientists has found that over 90% of dementia cases in China go undetected, with the… read more.
EMA Highlights by Gary Finnegan – The EMA’s Committee for Medicinal Products for Human Use (CHMP) has a new member: Ivana Mikacic has been nominated by Croatia which… read more.
EMA Highlights by Gary Finnegan – A new Healthcare Professionals’ Working Party (HCPWP) has been created by the European Medicines Agency in an effort to secure greater input… read more.
EMA Highlights by Gary Finnegan – The European Medicines Agency (EMA) must perform a delicate balancing act as it finds itself centre stage in the on-going debate about… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.